BioWorld MedTech

May 21, 2015

Renal Denervation Resurrected: After clinical setbacks, renal denervation reboots with clinicians taking the lead

PARIS — The launch of renal denervation for the control of resistant hypertension is destine to become a textbook case study in how not to market a medical device. Read More

Obesity study at Tufts: New obesity treatment blocks brain-to-stomach signals

Inside the Beltway: FDA adcomm says duodenoscopes require human factors

Hospitalar Med-Tech Fair: Companies look to Latin America to fill gap from Arab countries

IPR challenge: could up the ante of defending drug patents

Financings: Eli Lilly helps Companion complete Series B funding

Please Help MDD Improve: Take a moment to complete critical reader survey

EuroPCR notebook: Edwards pauses enrollment in FORTIS mitral valve program

World in Review: St. Jude launches Canadian implant of Prodigy system

Agreements/contracts: Philips signs research alliance with MIT to develop HealthTech

Daily M&A: Molex subsidiary in plan to acquire ProTek Medical

HIT BITS: CHLA launches ImageInbox app to make patient images accessible

MDD's Orthopedics Extra

Today's news in brief

BioWorld

BioWorld briefs for July 21, 2026.

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....

LIT-002 is strong candidate for autism and neuropathic pain

BioWorld Science

Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 21, 2026

New biomarker may improve RSV drug screening

BioWorld

Respiratory syncytial virus (RSV) infection is responsible for 3.2 million hospital admissions and about 118,000 deaths in children under 5 years of age. The...